Oncotelic adopts new bylaws with advance notice provisions for shareholder proposals.

Oncotelic Therapeutics, Inc.

Board adopted new amended and restated bylaws on May 18, 2023.
New bylaws add advance notice requirements for shareholder proposals at meetings or consent solicitations.
Replaces prior bylaws; full text filed as Exhibit 3.2.
No financial or operational changes reported.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Oncotelic Therapeutics, Inc.: Adopted new amended and restated by-laws containing new advance notice provisions for shareholder proposals and consent solicitations (effective 2023-05-18).

Change: bylaw amendment
Effective: 2023-05-18

Exact text from the filing

On May 18, 2023, the Board of Directors of Oncotelic Therapeutics, Inc. (the “ Company ”) adopted the new amended and restated by-laws (the “ New By-Laws ”) for the Company, replacing the prior amended and restated by-laws. The New By-Laws contain new provisions for advance notices by shareholders to propose items for consideration at future Annual Meetings or Consent Solicitations.

View on SEC.gov

24 governance changes filed in the last 30 days. Browse all governance changes →

Oncotelic Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-018380

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.